FibroGen (NASDAQ:FGEN) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of FibroGen (NASDAQ:FGEN) in a research report released on Friday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, William Blair restated a market perform rating on shares of FibroGen in a report on Monday, June 3rd.

FibroGen Trading Up 3.8 %

Shares of FGEN opened at $0.41 on Friday. The stock has a market capitalization of $40.43 million, a price-to-earnings ratio of -0.17 and a beta of 0.69. FibroGen has a 12 month low of $0.33 and a 12 month high of $2.93. The firm has a fifty day simple moving average of $0.51 and a 200 day simple moving average of $1.05.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.09. The company had revenue of $50.64 million during the quarter, compared to analyst estimates of $33.00 million. During the same period in the previous year, the company posted ($0.65) EPS. As a group, research analysts predict that FibroGen will post -0.91 earnings per share for the current fiscal year.

Institutional Trading of FibroGen

A number of institutional investors have recently bought and sold shares of FGEN. Point72 DIFC Ltd grew its position in FibroGen by 734.2% during the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 45,990 shares in the last quarter. Cubist Systematic Strategies LLC grew its holdings in shares of FibroGen by 3,906.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 280,161 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of FibroGen in the second quarter worth $130,000. Doheny Asset Management CA acquired a new position in FibroGen in the second quarter valued at about $48,000. Finally, AQR Capital Management LLC lifted its position in FibroGen by 139.6% during the second quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock worth $1,179,000 after purchasing an additional 769,586 shares during the period. Institutional investors own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.